Accuray's business model effectively combines capital equipment sales with a growing recurring services base, which supports revenue stability and margin improvement. The company's technology is differentiated but faces competitive pressure requiring ongoing innovation. Geographic diversification a…
Accuray (ARAY) Q3 2025: 12% Revenue Growth Underscores Resilience Amid Tariff Challenges
Accuray delivered solid year-over-year revenue growth driven by product and service expansion despite tariff headwinds in China. Operational discipline and strong service revenue underpinned a substantial adjusted EBITDA improvement. The company’s mitigation efforts and diversified global footprint position it to sustain performance amid ongoing geopolitical uncertainty.
Summary
- Resilient Demand Across Markets: Strong product and service revenue growth reflects broad customer adoption and expanding installed base.
- Operational Discipline: Focused cost management and working capital efficiency drove improved profitability and cash flow.
- Tariff Mitigation Focus: Strategic initiatives aim to offset China volume declines and protect margins amid uncertain trade policies.
Business Overview
Accuray Incorporated develops and sells radiation therapy treatment technologies primarily used in oncology and neuro-radiosurgery. The company generates revenue through two major segments: product sales, which include advanced radiation therapy systems, and a recurring services business that supports installed equipment via maintenance, training, and software subscriptions. Its global footprint includes developed and emerging markets, with a notable presence in the U.S., China, India, and other Asia Pacific regions.
Performance Analysis
In the third quarter of fiscal 2025, Accuray reported total net revenue of $113.2 million, marking a 12 percent increase year-over-year. Product revenue rose 16 percent to $57.3 million, driven by a 23 percent unit volume increase, signaling strong customer demand for its radiation therapy systems. Service revenue, representing approximately 49 percent of total revenue, grew 9 percent to $55.9 million, reflecting the company's growing installed base and higher pricing.
Gross margin contracted slightly to 27.9 percent from 28.7 percent in the prior year, primarily due to a $1.4 million net margin deferral related to shipments to its China joint venture, which delays margin recognition until end-customer delivery. This was partially offset by higher-margin service revenue contributions. Operating expenses declined 9 percent to $30.6 million, illustrating disciplined cost control. The company narrowed its net loss to $1.3 million from $6.3 million in the prior year, while adjusted EBITDA surged to $6 million, a more than fivefold increase, fueled by volume growth and operational improvements.
- Order Backlog and Book-to-Bill: The order backlog stood at $452 million, down approximately 10 percent year-over-year, with a book-to-bill ratio of 1.2, indicating healthy demand relative to shipments despite tariff-related uncertainty.
- Cash and Working Capital: Ending cash increased by $15 million sequentially to $79 million, supported by strong cash collections and inventory management, with inventory slightly reduced to $146 million.
- China Tariff Impact: Anticipated $10 to $15 million revenue headwind in Q4 due to tariffs restricting product shipments to China, partially offset by growth in other regions.
Overall, Accuray’s financial results demonstrate robust execution and resilience in a complex global environment, driven by diversified revenue streams and disciplined cost management.
Executive Commentary
"We achieved a strong third quarter and I am proud of the resiliency of the entire team and their focus on driving actions to mitigate the impact of the tariffs. Despite evolving global dynamics, our team's disciplined execution, clear strategy and the growing underlying demand for our innovative, distinct technologies gives us confidence in our ability to deliver sustained performance."
Suzanne Winter, President and Chief Executive Officer
"Net revenue for the third quarter was $113 million, which was up 12% versus the prior year and up 14% on a constant currency basis. Product revenue for the third quarter was $57 million, up 16% from the prior year and up 16% on a constant currency basis, reflecting a 23% increase in unit volume over the same time period."
Ali Pervez, Chief Financial Officer
Strategic Positioning
1. Diversified Revenue Model Balances Growth and Stability
Accuray’s business model balances higher-margin, cyclical product sales with a growing, stable recurring services revenue stream, which accounted for nearly half of total revenue this quarter. This diversification provides resilience against market volatility and tariff disruptions, as service revenue is less exposed to trade policy impacts.
2. Global Market Expansion with Focus on Emerging Regions
The company is actively expanding in emerging markets such as India and non-China Asia Pacific, leveraging strong demand and regional stimulus programs. Recent shipments to Myanmar and orders from Taiwan and Thailand exemplify this geographic diversification, helping to offset China-specific risks.
3. Tariff Mitigation and Supply Chain Adaptability
Facing $10 to $15 million quarterly revenue headwinds from China tariffs, Accuray is implementing multiple mitigation strategies including establishing a U.S. foreign trade zone, duty drawback on qualifying components, developing alternative domestic suppliers, and seeking tariff exemptions through its China joint venture partnership. These efforts aim to preserve margins and shipment volumes despite geopolitical uncertainty.
4. Operational Excellence and Cost Discipline
The company’s focus on reducing operating expenses by 9 percent year-over-year, alongside leaner inventory management, has enhanced profitability and cash flow. Investments in enterprise resource planning (ERP) and talent development are designed to improve operational agility and efficiency in a dynamic global environment.
5. Capital Structure Optimization Underway
Accuray is exploring refinancing and other capital structure alternatives to strengthen its financial flexibility and support long-term strategic goals. This proactive approach is critical given the ongoing market uncertainties and the need to fund innovation and growth initiatives.
Key Considerations
Accuray’s Q3 results highlight a company navigating complex external pressures with strategic focus and operational discipline. Key considerations for investors include:
- Tariff-Related Revenue Pressure: The near-term product revenue impact from China tariffs is significant but partially mitigated by growth in other regions and service revenue stability.
- Service Business as Margin Lever: Continued expansion and margin improvement in the service segment provide a predictable revenue base and profitability cushion.
- Order Backlog Composition: The order backlog remains substantial but has declined year-over-year, reflecting tightened booking criteria and tariff-related shipment delays.
- Supply Chain and Manufacturing Flexibility: Efforts to diversify sourcing and manufacturing footprint are critical to managing tariff risks and maintaining delivery schedules.
- Capital Allocation Focus: Refinancing efforts and cash generation will influence the company’s ability to invest in innovation and market expansion.
Risks
Accuray faces material risks from ongoing geopolitical tensions and trade policies that could further disrupt shipments, particularly in China. Supply chain constraints and inflationary pressures on labor and components may increase costs. The company’s ability to secure tariff exemptions and successfully implement mitigation strategies remains uncertain. Additionally, competitive pressures in radiation therapy technologies and regulatory approval delays could impact growth.
Forward Outlook
For the fiscal fourth quarter, Accuray guided revenue between $121 million and $129 million, reflecting tariff headwinds primarily in China. Adjusted EBITDA is expected in the range of $9.5 million to $12 million, supported by operational improvements and mitigation efforts. For the full fiscal year 2025, the company reaffirmed adjusted EBITDA guidance of $28.5 million to $31 million, while lowering total revenue guidance to $452 million to $460 million due to tariff impacts. Management emphasized ongoing monitoring of trade dynamics and expects clearer visibility on fiscal 2026 at the next earnings release.
Takeaways
Accuray’s Q3 performance underscores its ability to maintain growth and profitability amid complex external challenges. Investors should consider:
- Resilient Execution: The company’s disciplined cost management and operational agility have translated into meaningful adjusted EBITDA expansion despite tariff-related revenue pressures.
- Strategic Market Diversification: Expanding presence in emerging markets and a robust service business provide growth avenues and risk mitigation against China-specific disruptions.
- Monitoring Tariff Developments: The evolving trade landscape remains a key risk and opportunity factor; successful mitigation and tariff exemptions could accelerate recovery and margin expansion beyond FY25.
Conclusion
Accuray’s third quarter results demonstrate strong underlying demand, operational discipline, and proactive tariff mitigation efforts. While China tariffs pose a near-term revenue headwind, the company’s diversified business model and global footprint position it well to sustain growth and profitability. Investors should watch for evolving trade developments and capital structure initiatives as critical factors shaping the company’s trajectory.
Industry Read-Through
Accuray’s experience highlights broader industry challenges in medical technology companies with significant global supply chains and exposure to geopolitical risks. The tariff-driven disruption in China underscores the importance of diversified manufacturing footprints and service revenue streams in maintaining resilience. Other radiation therapy and medical device companies should monitor Accuray’s mitigation strategies and market shifts, especially as trade policies and supply chain dynamics remain fluid. The growing emphasis on service and software offerings as margin and growth drivers is a notable trend across healthcare technology sectors.